This week’s video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ - Free Report) , and International Paper (IP - Free Report) .
Johnson & Johnson (JNJ - Free Report) has the largest market capitalization for any U.S. healthcare company at just under $330 billion. The company’s Q1 earnings report beat both top and bottom line expectations with earnings and revenues improving by +12.6% year over year. Most importantly the Pharma segment, which accounts for almost half of the company’s total revenues had sales improve by +19%.
But after the earnings report, the stock price began to fall as worries about increasing competition from generic drugs would negatively impact Pharma sales. While JNJ has a nice pipeline of new drugs, and high expectations for its cancer and stroke prevention medications the segment was susceptible to encroachment by generic competitors. To counter this threat, management announced that it has about $50 billion available for acquisitions. Further, management commented that they were not looking to make one big $50 billion splash, rather they were looking to make many smaller acquisitions. These acquisitions are expected to bolster its drug pipeline for the next several years.
To add to this good news, JNJ recently announced that they accepted Platinum Equity’s $2.1 billion offer to sell the LifeScan business (diabetes treatments). This deal is expected to close in late 2018. Moreover, management revealed that Fortive Corp made a $2.8 billion offer to purchase the Advanced Sterilization Products Business, which if accepted would close in early 2019.
These proceeds from the sale of these units are expected to go into its acquisition pool, share repurchase program, and to be used for an increased dividend payment. Currently, JNJ is in a very unique group called Dividend Kings; a company that has increased dividend payments each year for the past 50 consecutive years. The company has a current annual dividend yield of +2.94%.
Price and Earnings Consensus Graph
As you can see in the graph below, the stock price had been on a steady upwards trend since the third quarter 2015. When the markets peaked in January of 2018, the stock price then fell for the next several months due to generic competition worries.
This week’s video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ - Free Report) , and International Paper (IP - Free Report) .
Johnson & Johnson (JNJ - Free Report) has the largest market capitalization for any U.S. healthcare company at just under $330 billion. The company’s Q1 earnings report beat both top and bottom line expectations with earnings and revenues improving by +12.6% year over year. Most importantly the Pharma segment, which accounts for almost half of the company’s total revenues had sales improve by +19%.
But after the earnings report, the stock price began to fall as worries about increasing competition from generic drugs would negatively impact Pharma sales. While JNJ has a nice pipeline of new drugs, and high expectations for its cancer and stroke prevention medications the segment was susceptible to encroachment by generic competitors. To counter this threat, management announced that it has about $50 billion available for acquisitions. Further, management commented that they were not looking to make one big $50 billion splash, rather they were looking to make many smaller acquisitions. These acquisitions are expected to bolster its drug pipeline for the next several years.
To add to this good news, JNJ recently announced that they accepted Platinum Equity’s $2.1 billion offer to sell the LifeScan business (diabetes treatments). This deal is expected to close in late 2018. Moreover, management revealed that Fortive Corp made a $2.8 billion offer to purchase the Advanced Sterilization Products Business, which if accepted would close in early 2019.
These proceeds from the sale of these units are expected to go into its acquisition pool, share repurchase program, and to be used for an increased dividend payment. Currently, JNJ is in a very unique group called Dividend Kings; a company that has increased dividend payments each year for the past 50 consecutive years. The company has a current annual dividend yield of +2.94%.
Price and Earnings Consensus Graph
As you can see in the graph below, the stock price had been on a steady upwards trend since the third quarter 2015. When the markets peaked in January of 2018, the stock price then fell for the next several months due to generic competition worries.
Get the latest research report on JNJ - FREE
Get the latest research report on IP - FREE